News
Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...
Investor's Business Daily on MSN1d
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli LillyNovo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback